Abstract
Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called "Ketorolac in Breast Cancer trial" (KBCt) (NCT01806259).
Copyright © 2013 Elsevier Ltd. All rights reserved.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Breast Neoplasms / complications
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / surgery
-
Female
-
Humans
-
Inflammation / complications
-
Inflammation / drug therapy*
-
Ketorolac / administration & dosage
-
Ketorolac / pharmacology*
-
Ketorolac / therapeutic use
-
Patient Selection
-
Perioperative Period*
-
Randomized Controlled Trials as Topic / methods
-
Sample Size
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Ketorolac
Associated data
-
ClinicalTrials.gov/NCT01806259